These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23186806)

  • 21. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction.
    Badheka AO; Rathod A; Kizilbash MA; Bhardwaj A; Ali O; Afonso L; Jacob S
    Am J Cardiol; 2011 Nov; 108(9):1283-8. PubMed ID: 21855829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of digoxin in atrial fibrillation: One step further in the mortality controversy from the AFFIRM study.
    Charnigo R; Khairy P; Guo J; Shohoudi A; Elayi CS
    Pacing Clin Electrophysiol; 2018 Jul; 41(7):713-719. PubMed ID: 29660142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation.
    Ouyang AJ; Lv YN; Zhong HL; Wen JH; Wei XH; Peng HW; Zhou J; Liu LL
    Am J Cardiol; 2015 Apr; 115(7):901-6. PubMed ID: 25660972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of rate versus rhythm control in patients with atrial fibrillation and a pacemaker.
    Badheka AO; Marzouka GR; Rathod AD; Patel NJ; Myerburg RJ; Mitrani RD
    Am J Cardiol; 2013 Jun; 111(12):1759-63. PubMed ID: 23540545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Lip GY
    Eur J Heart Fail; 2013 Apr; 15(4):415-24. PubMed ID: 23302606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Digoxin Use Among Medicaid Enrollees With Atrial Fibrillation.
    Adedinsewo D; Xu J; Agasthi P; Oderinde A; Adekeye O; Sachdeva R; Rust G; Onwuanyi A
    Circ Arrhythm Electrophysiol; 2017 May; 10(5):e004573. PubMed ID: 28500174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digoxin and Mortality in Patients With Atrial Fibrillation.
    Lopes RD; Rordorf R; De Ferrari GM; Leonardi S; Thomas L; Wojdyla DM; Ridefelt P; Lawrence JH; De Caterina R; Vinereanu D; Hanna M; Flaker G; Al-Khatib SM; Hohnloser SH; Alexander JH; Granger CB; Wallentin L;
    J Am Coll Cardiol; 2018 Mar; 71(10):1063-1074. PubMed ID: 29519345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure.
    Frasure-Smith N; Lespérance F; Habra M; Talajic M; Khairy P; Dorian P; Roy D;
    Circulation; 2009 Jul; 120(2):134-40, 3p following 140. PubMed ID: 19564557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update.
    Vamos M; Erath JW; Benz AP; Lopes RD; Hohnloser SH
    Am J Cardiol; 2019 Jan; 123(1):69-74. PubMed ID: 30539748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry.
    Migaj J; Kałużna-Oleksy M; Nessler J; Opolski G; Crespo-Leiro MG; Maggioni AP; Grajek S; Ponikowski P; Drożdż J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(7):1064-1072. PubMed ID: 29476617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Digoxin Use and Adverse Outcomes Among Patients in the Chinese Atrial Fibrillation Registry.
    Gao Y; Chang S; Du X; Dong J; Xu X; Zhou Y; Lip GYH; Ma C
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):579-587. PubMed ID: 31077081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
    Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Digoxin-associated mortality: a systematic review and meta-analysis of the literature.
    Vamos M; Erath JW; Hohnloser SH
    Eur Heart J; 2015 Jul; 36(28):1831-8. PubMed ID: 25939649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis.
    Chen Y; Cai X; Huang W; Wu Y; Huang Y; Hu Y
    Medicine (Baltimore); 2015 Dec; 94(52):e2409. PubMed ID: 26717399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AF-CHF Substudy.
    Dyrda K; Roy D; Leduc H; Talajic M; Stevenson LW; Guerra PG; Andrade J; Dubuc M; Macle L; Thibault B; Rivard L; Khairy P
    J Cardiovasc Electrophysiol; 2015 Dec; 26(12):1327-32. PubMed ID: 26332293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis.
    Elayi CS; Shohoudi A; Moodie E; Etaee F; Guglin M; Roy D; Khairy P;
    Int J Cardiol; 2020 Aug; 313():48-54. PubMed ID: 32320783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a role for digoxin in atrial fibrillation without heart failure?
    Master J; Schweitzer P
    Cardiol J; 2009; 16(5):483-6. PubMed ID: 19753533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-dependent prognostic significance of atrial fibrillation in outpatients with chronic heart failure: data from the Italian Network on Congestive Heart Failure Registry.
    Baldasseroni S; Orso F; Fabbri G; De Bernardi A; Cirrincione V; Gonzini L; Fumagalli S; Marchionni N; Midi P; Maggioni AP;
    Cardiology; 2010; 116(2):79-88. PubMed ID: 20516683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Curtis AB; Gersh BJ; Corley SD; DiMarco JP; Domanski MJ; Geller N; Greene HL; Kellen JC; Mickel M; Nelson JD; Rosenberg Y; Schron E; Shemanski L; Waldo AL; Wyse DG;
    Am Heart J; 2005 Apr; 149(4):645-9. PubMed ID: 15990747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.